So, Todd, this is not a done deal. It's still in the early consideration stages. But your reporting shows we're talking about the IRS, which is part of the Treasury Department.How far along the process do we think they are. It's unclear. We just know that the Treasury is considering these proposals.The Office of Tax Policy, where, you know, these sorts of rules are normally drafted and considered is, you know, you know, discussing the possibility of codifying, you know, what Trump has threatened Harvard wit ...

Intapp (INTA) Update / Briefing June 12, 2025 11:30 AM ET Speaker0 Wonderful. Alrighty. Well, thank you very much, everyone, for making the time to join today's webinar, Beyond Traditional Sourcing, Discovering Opportunities with AI Origination and Private Capital. Before we get started today, I would like to just quickly say this presentation may contain information regarding future services, features, or functionality that are not currently available. The timing and delivery of these features, functions, ...

CNBC's Eamon Javers joins 'Monet Movers' to discuss the latest from U.S. Treasury Secretary Scott Bessent's testimony before the Senate Finance Committee. ...

taking care of tomorrow today when future you overwhelms present you in high school. Picture this. It's a Wednesday night and you're sitting at your desk surrounded by textbooks, unfinished assignments, and a growing sense of panic.A big test looms tomorrow. Your phone buzzes. It's your girlfriend texting you that it's her girlfriend's that it's her grandmother's birthday party and you're invited.You think about it and hesitate. Should you go. Why not.You go and you get this sense of relief when you get the ...

[Music] I want you to imagine that you're sat in a meeting at the National Grid and the topic replacing a critical system that manages the entirety of the UK's infrastructure. There's an incumbent supply of over 20 years and then someone suggests bringing in a team that have never worked in the energy sector before. Sounds crazy, right.Well, that's exactly what happened with Alexa, one of our key clients. And not only did we succeed, we created something that energy professionals now use and praise every si ...

Core Insights - Novavax announced positive results from a late-stage study of its COVID-19-influenza combination (CIC) and standalone influenza vaccine candidates, showing robust immune responses in adults aged 65 and older [1][2][8] - The study's findings will guide the design of another late-stage trial that could support regulatory submissions if successful [3][8] - Novavax is seeking strategic collaborations to finance further development and commercialization of both vaccine candidates as part of a strategic shift to expand its pipeline [4][8] Stock Performance - Novavax shares have underperformed the industry year to date [5] Recent Developments - The announcement followed the FDA's approval of Nuvaxovid for older adults, with a narrower label than expected, restricting use in individuals aged 12-64 with high-risk conditions [7][8] - Sanofi has acquired exclusive global marketing rights for Nuvaxovid, part of a multi-billion-dollar deal, and will receive tiered royalties on future sales [10] Competitive Landscape - Other companies like Pfizer and Moderna are also developing COVID-flu combination vaccines, with Moderna ahead in its investigational candidate mRNA-1083, despite a recent setback [11][12] - Pfizer faced challenges in its phase III study for its combination vaccine, missing one of its primary immunogenicity objectives [13] - Sanofi is testing multiple COVID-19/flu combination vaccine candidates, with two receiving fast-track designation from the FDA [14]

The Senate continues to work on changes to the House passed reconciliation bill with their looming July 4th deadline. Joining us right now with the latest is Senator Shelley Moore Capo. She is the Republican Policy Committee chair.And um Senator, thank you for being with us. Let's talk a little bit about where things stand because we we've heard from many of your colleagues who have had issues with this bill as it stands and want to change things. What what's the latest.Well, we always knew when the House p ...

Core Insights - TOMI Environmental Solutions, Inc. has been awarded the "Disinfection and Decontamination Products Company of the Year 2025" by MedTech Outlook, showcasing its commitment to excellence and customer trust in its SteraMist iHP technology [1][2][3] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology® (BIT™) platform, which employs a low percentage of hydrogen peroxide as the active ingredient [4] - The SteraMist systems incorporate patented ionized Hydrogen Peroxide (iHP™) technology, providing superior disinfection across various sectors, including healthcare, pharmaceuticals, and food processing [4] Recognition and Commitment - The award selection involved an expert panel of C-level executives and industry leaders, affirming SteraMist's leadership in the disinfection and decontamination market for 2025 [2] - The CEO of TOMI expressed gratitude for the recognition, emphasizing the company's dedication to advancing its iHP technology and exceeding customer expectations globally [3]

Core Insights - Incannex Healthcare Inc. has successfully canceled all remaining Series A Warrants, eliminating potential dilution ahead of key Phase 2 clinical milestones [1][2][3] - The cancellation involved a total of 347.2 million shares, with a financial commitment of $12.2 million for the final tranche [2][3] - The company is preparing for the upcoming topline data readout from its Phase 2 RePOSA trial of IHL-42X for obstructive sleep apnea, expected in July 2025 [3][6] Company Overview - Incannex is a clinical-stage biopharmaceutical company focused on developing combination drug therapies for high-impact indications, including obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [8] - The lead product candidate, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide, designed to target the underlying mechanisms of obstructive sleep apnea [5][8] - IHL-42X is currently in a Phase 2/3 clinical trial, with over 560 patients expected to be enrolled globally [5][6] Product Details - IHL-42X targets two physiological pathways associated with obstructive sleep apnea: intermittent hypoxia and hypercapnia [6][7] - Previous trials indicated that IHL-42X reduced the Apnea-Hypopnea Index by an average of 51% at the lowest dosage [6] - The product aims to address a significant gap in care for the estimated 1 billion people affected by obstructive sleep apnea globally, particularly those who are not classified as obese [7]

>> SUPERPOWER OF A. >> GREAT NIGHT'S SLEEP. >> IN 2005, WHEN THE CITY OF NEW ORLEANS WAS IN A DIRE STATE OF EMERGENCY FROM HURRICANE KATRINA.>> AND ITS AFTERMATH. >> THOUSANDS OF. NATIONAL GUARD.MEMBERS WERE SENT THERE TO HELP WITH RESCUE AND RELIEF AT THE REQUEST OF THE STATE'S GOVERNOR AT THE TIME. AND WHILE PEOPLE WERE REALLY HAPPY TO GET FEDERAL HELP, IT WAS ALSO OBVIOUSLY SOMETHING NEW AND SCARY TO HAVE MILITARY TROOPS ON THEIR STREETS. AND THERE WAS THIS MEMORABLE SCENE CAPTURED IN SPIKE LEE'S DOCUMEN ...